Literature DB >> 19363209

Biomarkers of heart failure in pleural fluid.

José M Porcel1, Montserrat Martínez-Alonso2, Gonzalo Cao3, Silvia Bielsa4, Ana Sopena3, Aureli Esquerda3.   

Abstract

BACKGROUND: The objective of this study was to compare the diagnostic accuracy of pleural fluid brain natriuretic peptide (BNP), N-terminal pro-BNP (NT-pro-BNP) and ST2, which are biomarkers of myocyte stress, for diagnosing pleural effusions due to heart failure (HF). BNP and ST2 have not been previously evaluated in pleural fluid.
METHODS: The three biomarkers were measured in the pleural fluid of 90 cardiac effusions and 91 noncardiac effusions by commercially available methodologies. The area under the curve (AUC) quantified the overall diagnostic accuracy of the tests.
RESULTS: Pleural fluid NT-pro-BNP, BNP, and ST2 demonstrated AUCs of 0.96, 0.90 and 0.59, respectively, for diagnosing effusions due to HF. The cutoff values of 1,300 and 115 pg/mL, respectively, for NT-pro-BNP and BNP had the best discriminating properties. The reference level for BNP was particularly accurate in men > 75 years of age (AUC, 0.98), but age, gender, and serum creatinine level did not influence the NT-pro-BNP levels. Of the 20 patients whose cardiac effusions were misclassified as exudates by the criteria of Light et al, 18 patients (90%) and 14 patients (70%), respectively, would have been correctly categorized by NT-pro-BNP and BNP, whereas only 10 patients (50%) would have been appropriately classified by the serum-pleural protein gradient.
CONCLUSIONS: The pleural fluid NT-pro-BNP level is very useful in establishing the diagnosis of HF-associated effusions, and it confirms this diagnosis better than pleural BNP levels. The measurement of NT-pro-BNP rather than the serum-to-pleural protein gradient is recommended for identifying mislabeled cardiac transudates. The pleural fluid ST2 level is not helpful in diagnosing HF.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19363209     DOI: 10.1378/chest.09-0270

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  7 in total

1.  Comparison of pleural fluid N-terminal pro-brain natriuretic peptide and brain natriuretic-32 peptide levels.

Authors:  Ann C Long; Hollis R O'Neal; Suiwei Peng; Kirk B Lane; Richard W Light
Journal:  Chest       Date:  2010-02-05       Impact factor: 9.410

Review 2.  Diagnostic accuracy of pleural fluid NT-pro-BNP for pleural effusions of cardiac origin: a systematic review and meta-analysis.

Authors:  Surinder Janda; John Swiston
Journal:  BMC Pulm Med       Date:  2010-11-20       Impact factor: 3.317

3.  Role of IL-33 in inflammation and disease.

Authors:  Ashley M Miller
Journal:  J Inflamm (Lond)       Date:  2011-08-26       Impact factor: 4.981

Review 4.  Diagnostic Accuracy of Natriuretic Peptides for Heart Failure in Patients with Pleural Effusion: A Systematic Review and Updated Meta-Analysis.

Authors:  Zhi-Jun Han; Xiao-Dan Wu; Juan-Juan Cheng; Shi-Di Zhao; Ming-Zhu Gao; Hong-Yu Huang; Bing Gu; Ping Ma; Yan Chen; Jun-Hong Wang; Cheng-Jian Yang; Zi-He Yan
Journal:  PLoS One       Date:  2015-08-05       Impact factor: 3.240

5.  Cautious application of pleural N-terminal pro-B-type natriuretic peptide in diagnosis of congestive heart failure pleural effusions among critically ill patients.

Authors:  Jiann-Horng Yeh; Chun-Ta Huang; Chia-Hsiung Liu; Sheng-Yuan Ruan; Yi-Ju Tsai; Ying-Chun Chien; Ching-Yao Yang; Chun-Kai Huang; Chia-Lin Hsu; Lu-Cheng Kuo; Pei-Lin Lee; Shih-Chi Ku; Ping-Hung Kuo; Chong-Jen Yu
Journal:  PLoS One       Date:  2014-12-12       Impact factor: 3.240

Review 6.  Pleural, peritoneal and pericardial effusions - a biochemical approach.

Authors:  Lara Milevoj Kopcinovic; Jelena Culej
Journal:  Biochem Med (Zagreb)       Date:  2014-02-15       Impact factor: 2.313

Review 7.  Biomarkers in the diagnosis of pleural diseases: a 2018 update.

Authors:  José M Porcel
Journal:  Ther Adv Respir Dis       Date:  2018 Jan-Dec       Impact factor: 4.031

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.